In this study, we investigated associations of PGSAUD with the probability of remission among participants with lifetime AUD from four distinct samples: COGA, comprising interviewed participants from (1) EA and (2) AA families with high familial risk for AUD and comparison families, and two cohorts of participants from the Indiana Biobank ascertained for (3) liver diseases or (4) substance use disorders. We hypothesized that higher PGSAUD, which indexes greater genetic liability to AUD and AUD severity, would be associated with decreased likelihood of remission. We found that higher PGSAUD were associated with decreased remission probability for COGA EA 12-month and non-abstinent remission, as expected, but that PGSAUD had the opposite direction of effect in Indiana Biobank liver diseases cohort, where higher PGSAUD were associated with increased probability of remission. No association of PGSAUD with COGA EA abstinent remission, COGA AA remission (12-month, abstinent, or non-abstinent), or Indiana Biobank SUD cohort remission was found.
